Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine

Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine

Introduction: Basal and intermediate insulin is available as U-100 (glargine, determir, NPH) or ultra-long-acting (ULA) U-200 (degludec) or U-300 (glargine). Insulins may be substituted with other insulin formulations based on financial factors, formulary preferences, patient preference, and patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Natalie Rosario, Cami Hunger, Allison Pettijohn, K’bria Whaley, Andrea Pabon, Valeria Hohl, Bernadette Asias-Dinh, Jodie Gee, Joshua Wollen
Format: Article
Language:English
Published: SAGE Publishing 2025-03-01
Series:Journal of Primary Care & Community Health
Online Access:https://doi.org/10.1177/21501319251327318
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items